Holen Sie sich die Stockscreener-App
4.87
2.40%
-0.12
Schlusskurs vom Vortag:
$4.99
Offen:
$5.04
24-Stunden-Volumen:
1.62M
Relative Volume:
1.19
Marktkapitalisierung:
$708.05M
Einnahmen:
$28.94M
Nettoeinkommen (Verlust:
$-54.29M
KGV:
-10.48
EPS:
-0.4647
Netto-Cashflow:
$-26.02M
1W Leistung:
+5.64%
1M Leistung:
-3.37%
6M Leistung:
+216.23%
1J Leistung:
+202.48%
1-Tages-Spanne:
$4.81
$5.09
1-Wochen-Bereich:
$4.55
$5.09
52-Wochen-Spanne:
$1.30
$5.43
Omniab Inc Stock (OABI) Company Profile
Firmenname
Omniab Inc
Sektor
Branche
Telefon
510-250-7800
Adresse
5980 HORTON STREET, EMERYVILLE
Compare OABI vs VRTX, MRNA, REGN, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
OABI
Omniab Inc
|
4.87 | 670.25M | 28.94M | -54.29M | -26.02M | -0.4647 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Omniab Inc Stock (OABI) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-11-29 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-04-21 | Eingeleitet | The Benchmark Company | Buy |
| 2023-04-13 | Eingeleitet | Craig Hallum | Buy |
| 2023-02-22 | Eingeleitet | Cowen | Outperform |
| 2023-02-13 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-12-20 | Eingeleitet | Truist | Buy |
| 2022-12-16 | Eingeleitet | Credit Suisse | Outperform |
| 2022-11-29 | Eingeleitet | SVB Leerink | Outperform |
| 2022-11-28 | Eingeleitet | Stifel | Buy |
Alle ansehen
Omniab Inc Aktie (OABI) Neueste Nachrichten
OmniAb Q2 2026 Earnings: Narrower-Than-Expected Loss Lifts SharesGuidance Revision Trend - siam.in
OmniAb (OABI) Shares Rise 2.80% to $4.59 as Stock Holds Mid-RangeValue Area Low - dars.gov.et
OmniAb, Inc.Common Stock (Nasdaq:OABI) Detailed Stock Data - The Chronicle-Journal
OmniAb to Host Investor & Analyst Day on October 6, 2026 - BioSpace
Lab tours and technology demos are planned for Oct. 6 - stocktitan.net
OmniAb (OABI) Slips 5.31% to $4.01 as Sellers Test Near-Term SupportInstitutional Buy Signals - dars.gov.et
OmniAb Inc. OABI Stock Holds Support As Traders Weigh Weak Margins - StocksToTrade
OmniAb Inc. Stock Holds Range As Traders Weigh Deep Losses Against Strong Balance Sheet - timothysykes.com
Biotech Stocks At 52-Week HighsOABI +13%, FRNM, EXEL, FTH, LFST - RTTNews
OmniAb Company Profile & Introduction - Moomoo
OABI Looks 50.3% Overvalued on GF Value™ - GuruFocus
Is OmniAb (OABI)’s Eli Lilly (LLY) Partnership a Game Changer for OABI? - finance.yahoo.com
OmniAb to Participate in Upcoming Investor Conferences - Yahoo Finance
OmniAb (OABI) Earnings Reading: EPS Beats Its Estimate at the Close; Post-Earnings: The Share Price Adds 8.78%Earnings Yield Analysis - dars.gov.et
OmniAb (OABI) Results at a Glance: The Available Earnings Metric Delivers a Beat in the Latest Session; Post-Report: The Market Price Moves 0.70% Higher at the CloseEarnings Stability Report - vinanet.vn
OmniAb (OABI) Quarter in Focus: The Available Earnings Metric Delivers a Beat; Share Move: The Market Price Moves 1.79% Higher at the CloseBanking Earnings Report - vinanet.vn
OmniAb secures up to $370m Lilly deal for ion channel program - BioXconomy
Truist Financial Maintains OmniAb(OABI.US) With Buy Rating - Moomoo
OmniAb signs $370 million ion channel discovery deal with Eli Lilly - The Pharma Letter
OmniAb boosts 2026 cash guidance after milestone-rich Eli Lilly deal validates its biotech platform. - Pluang
M&A Roundup: LEO Pharma Acquires Dersimelagon, BioMarin Acquires Alesta, OmniAb Enters collaboration with Eli Lilly, Chugai and GSK Enter License Agreement for AID351 - Pharmaceutical Executive
Analysts Offer Insights on Healthcare Companies: OmniAb (OABI), Neurocrine (NBIX) and Evaxion Biotech (EVAX) - The Globe and Mail
OmniAb: Lilly-Style Partners Paying Attention To This Early-Stage Biotech (NASDAQ:OABI) - Seeking Alpha
Craig-Hallum Maintains OmniAb(OABI.US) With Buy Rating, Maintains Target Price $7 - Moomoo
OmniAb Jumps 18% as Lilly Deal Lifts Cash Outlook - TradingView
Eli Lilly Signs $370 Million Ion Channel Deal With OmniAb, Sending Shares Surging - finance.biggo.com
OABI Reiterates by HC Wainwright & Co. -- Price Target Maintained at $11.00 - GuruFocus
Lilly taps OmniAb for ion channel discovery in deal worth up to USD 370m - AllSci
Lilly to pay up to $370M for OmniAb collab; Slate, Fulcrum forge reverse merger - Endpoints News
OmniAb Raises 2026 Financial Guidance - BioSpace
$OmniAb (OABI.US)$ - Moomoo
OmniAb Inc. (OABI) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
OmniAb (OABI) Stock Pops As Earnings Beat Resets Growth Outlook - timothysykes.com
Why Is Omniab Stock Rallying After Eli Lilly Deal? - Benzinga
OmniAb (OABI) Stock Surges After Big Q2 Earnings Beat - StocksToTrade
Why is OmniAb stock surging today? By Investing.com - Investing.com South Africa
OABI Looks 15.8% Overvalued on GF Value™ - GuruFocus
Why is OmniAb stock surging today? - Investing.com
OmniAb (OABI) Jumps As Earnings Beat Fuels Bullish Outlook - StocksToTrade
Lilly pens $370M deal with OmniAb for ion channel collab, but details remain vague - Fierce Biotech
OmniAb raises 2026 cash guidance to $49-$53 million range - scanx.trade
OmniAb lifts 2026 cash outlook following licensing momentum - Yahoo Finance
OmniAb raises 2026 cash guidance on licensing activity By Investing.com - Investing.com Canada
OmniAb Announces Global Collaboration and License Agreement for Ion Channel Program with Eli Lilly & Company - Finviz
OmniAb partners with Eli Lilly on ion channel program By Investing.com - Investing.com Canada
OmniAb raises 2026 cash guidance on licensing activity - Investing.com
OmniAb, Inc. And Eli Lilly And Company Announce Global Collaboration And License Agreement For Ion Channel Program - marketscreener.com
Whitefort Capital group reports 7.1% OmniAb (OABI) ownership in amended filing - Stock Titan
OmniAb (OABI) Q2 2026 Earnings Call Transcript - AOL.com
Dimensional Fund Advisors LP Has $2.74 Million Stake in OmniAb, Inc. $OABI - marketbeat.com
OmniAb Inc (OABI) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Finanzdaten der Omniab Inc-Aktie (OABI)
Umsatz
Nettogewinn
Free Cashflow
ENV
Omniab Inc-Aktie (OABI) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| FOEHR MATTHEW W | President and CEO |
Apr 07 '26 |
Option Exercise |
0.00 |
36,459 |
0 |
4,439,736 |
| FOEHR MATTHEW W | President and CEO |
Apr 07 '26 |
Sale |
1.49 |
19,244 |
28,674 |
4,420,492 |
0.05%
0.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):